secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-07-10T01:06:20+00:00
Accession:  0001104659-26-082341
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio completes enrollment of 850 patients in pivotal Phase 3 AD trial of buntanetap
--------------------------------------------------------------------------------

- Enrolled 850 pTau217-confirmed early AD patients across 83 US sites, exceeding original projections.
- Symptomatic top-line data expected Q1 2027; disease-modifying data expected Q1 2028.
- Company plans two NDA submissions to FDA after each respective data readout.
- Trial is randomized, placebo-controlled, double-blind with daily oral buntanetap 30mg.
- Last patient completes 6-month treatment in January 2027; study on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/0001104659-26-082341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/tm2620172d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer